A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

NCT01125514 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Aliskiren 150 mg
DRUG: Furosemide 60 mg
DRUG: Placebo for Aliskiren
DRUG: Aliskiren 300 mg

Sponsor

Novartis Pharmaceuticals